Martin Edwards's Net Worth
$3.42 Million
Who is Martin Edwards?
Martin Edwards has an estimated net worth of $3.42 Million. This is based on reported shares across multiple companies, which include Morphic Holding, Inc., REATA PHARMACEUTICALS INC, Verona Pharma plc, KalVista Pharmaceuticals, Inc., Inozyme Pharma, Inc., and CoLucid Pharmaceuticals, Inc..
SEC CIK
Martin Edwards's CIK is 0001640073
Past Insider Trading and Trends
2022 was Martin Edwards's most active year for acquiring shares with 9 total transactions. Martin Edwards's most active month to acquire stocks was the month of May. 2023 was Martin Edwards's most active year for disposing of shares, totalling 9 transactions. Martin Edwards's most active month to dispose stocks was the month of August. 2023 saw Martin Edwards paying a total of $293,130.14 for 164,768 shares, this is the most they've acquired in one year. In 2021 Martin Edwards cashed out on 25,712 shares for a total of $23,699.68, their largest year based on trade value.
Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
Morphic Holding, Inc. (MORF) No price found
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 4
| |||
Form 4
|
∞
| 2.38K |
$20.54 | $48,803.04 | 2.38K |
Nov 13
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 1
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 8
| |||
Form 4/A
|
—
|
0
|
—
|
—
|
0
|
Jun 16
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 16
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Dec 1
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
No matching records found |
REATA PHARMACEUTICALS INC No price found
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
---|---|---|---|---|---|---|---|---|---|
Form 4
| -100.00% | -6.12K |
—
|
—
|
0
|
Sep 26
| |||
Form 4
| +42.20% | 1.81K |
$93.61 | $169,902.15 | 6.12K |
Jun 7
| |||
Form 4
| +7,189.83% | 4.24K |
$34.76 | $147,451.92 | 4.3K |
Jun 8
| |||
Form 4
|
∞
| 59 |
$27.32 | $1,611.88 | 59 |
Jan 3
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 10
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Aug 3
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
No matching records found |
Verona Pharma plc (VRNA) Snapshot price: $26.39
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
—
|
—
|
0
|
Apr 29
| |||
Form 4
| +30.38% | 33.74K |
$1.84 | $61,973.03 | 144.8K |
Nov 20
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Apr 28
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Apr 28
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Aug 9
| |||
Form 4
| -9.77% | -12.02K |
$0.84 | -$10,096.55 | 111.06K |
Scheduled
|
May 4
| ||
Form 4
| -10.01% | -13.69K |
$0.99 | -$13,603.13 | 123.09K |
Scheduled
|
Feb 1
| ||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
No matching records found |
KalVista Pharmaceuticals, Inc. (KALV) Snapshot price: $12.34
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
—
|
—
|
0
|
Sep 30
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Oct 1
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 26
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
No matching records found |
Inozyme Pharma, Inc. (INZY) Snapshot price: $4.98
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 18
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 13
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 10
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 23
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jul 23
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
No matching records found |